The announcement came just one day after the company reported results that support ongoing Phase 1/2 AUGMENT-101 trial of Syndax its lead Menin-MLL inhibitor, SNDX-5613, for the treatment of adults with relapsed/refractory acute leukemias, including NPM1 mutant AML. The firm made the announcement that "Science magazine has published a preclinical report titled supporting the potential role of MLL1-Menin inhibition in the management of nucleophosmin (NPM1) mutant acute myeloid leukemia (AML)."